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University, Atlanta, GA, USAA B S T R A C TBackground: Phase 3 randomized trials have shown that mainte-
nance rituximab (MR) therapy or radioimmunotherapy (RIT) consol-
idation following frontline therapy can improve progression-free
survival for patients with follicular lymphoma (FL), but the cost-
effectiveness of these approaches with respect to observation has
not been examined using a common modeling framework. Objectives:
To evaluate and compare the economic impact of MR and RIT
consolidation versus observation, respectively, following the ﬁrst-
line induction therapy for patients with advanced-stage FL. Methods:
We developed Markov models to estimate patients’ lifetime costs,
quality-adjusted life-years (QALYs), and life-years (LYs) after MR, RIT,
and observation following frontline FL treatment from the US payer’s
perspective. Progression risks, adverse event probabilities, costs, and
utilities were estimated from clinical data of Primary RItuximab and
MAintenance (PRIMA) trial, Eastern Cooperative Oncology Group
(ECOG) trial (for MR), and First-line Indolent Trial (for RIT) and the
published literature. We evaluated the incremental cost-effectiveness
ratio for direct comparisons between MR/RIT and observation. Model
robustness was addressed by one-way and probabilistic sensitivityee front matter Copyright & 2015, International S
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ndence to: Christopher R. Flowers, 1365 Clifton Roaanalyses. Results: Compared with observation, MR provided an addi-
tional 1.089 QALYs (1.099 LYs) and 1.399 QALYs (1.391 LYs) on the
basis of the PRIMA trial and the ECOG trial, respectively, and RIT
provided an additional 1.026 QALYs (1.034 LYs). The incremental cost
per QALY gained was $40,335 (PRIMA) or $37,412 (ECOG) for MR and
$40,851 for RIT. MR and RIT had comparable incremental QALYs
before ﬁrst progression, whereas RIT had higher incremental costs
of adverse events due to higher incidences of cytopenias. Conclu-
sions: MR and RIT following frontline FL therapy demonstrated
favorable and similar cost-effectiveness proﬁles. The model results
should be interpreted within the speciﬁc clinical settings of each trial.
Selection of MR, RIT, or observation should be based on patient
characteristics and expected trade-offs for these alternatives.
Keywords: cost-effectiveness, follicular lymphoma, lymphoma,
maintenance, non-Hodgkin lymphoma, radioimmunotherapy,
rituximab.
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Follicular lymphoma (FL) is the most common subtype of indo-
lent non-Hodgkin’s lymphoma in the United States (US) [1,2],
accounting for approximately 20% of 580,000 prevalent non-
Hodgkin’s lymphoma cases in 2011 [1,3]. Although FL in limited
stage is curable with standard radiation therapy [4], most of the
patients with FL are diagnosed with advanced-stage disease [5,6],
which remains incurable. FL management also produces an
economic burden to patients and the US society, with an annual
cost ranging from $20,000 to $36,000 per patient [7].This cost is associated with substantial patient beneﬁt. In the
past few decades, the median overall survival (OS) of patients with
FL signiﬁcantly improved from 11 years to 18 years, following
advances in effective therapies and supportive care [8]. In the
modern era, chemotherapy and rituximab plus chemotherapy (R-
chemotherapy) have commonly been used for previously
untreated patients with advanced-staged FL. In current practice,
however, there is no single approach that has become the stand-
ard for ﬁrst-line treatment [9]. Advanced-stage FL typically produ-
ces a course of recurrent remissions and relapses with reducing
response rate, remission duration, and health-related quality ofociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 1 8 9 – 1 9 7190life (HRQOL) along with subsequent treatments. As a result, in the
absence of curative therapies, many efforts have focused on
extending the duration of the ﬁrst remission to postpone subse-
quent treatment and to help patients maintain a higher HRQOL.
Maintenance with rituximab (MR) and radioimmunotherapy
(RIT) consolidation are two approaches aiming at such improve-
ment. Rituximab, an anti-CD20 monoclonal antibody with favorable
toxicity proﬁle, has been a major therapeutic advance for FL
treatment in the last several decades. It has been used as a single
agent, in combination with chemotherapy, or as maintenance
therapy in newly diagnosed and relapsed patients [10]. Patients
undergoing MR following the induction therapy continue to receive
rituximab for an additional 2 years. RIT uses radiation-labeled anti-
CD20 antibody to deliver radiation tomalignant cells. It ﬁrst showed
a high response rate in patients with relapsed FL [11] and was later
applied as a consolidation strategy following ﬁrst-line treatment.
For untreated patients with FL, MR and RIT consolidation also
have demonstrated clinical beneﬁt. MR for 2 years has been shown
to signiﬁcantly improve the progression-free survival (PFS, i.e., time
from randomization to disease progression or death) and the rate of
complete response (i.e., complete disappearance of all evidence of
disease [12]) in the randomized Primary RItuximab and MAinte-
nance (PRIMA) and Eastern Cooperative Oncology Group (ECOG)
trials [13,14]. RIT consolidation following induction chemotherapy
or R-chemotherapy also showed similar efﬁcacy results in the
randomized First-line Indolent Trial (FIT) [15,16]. Each approach
demonstrated an improvement in PFS over observation without
producing signiﬁcant differences in patients’ HRQOL [14,17]. As a
result, MR and RIT consolidation have been approved for use in the
frontline setting since 2011 and 2009, respectively. A randomized
phase 2 trial, ZAR2007, will provide a head-to-head comparison
between MR and RIT following ﬁrst-line induction with R-CHOP
(rituximab, cyclophosphamide, doxorubicin, vincristine, and pre-
dnisone) therapy [18]. Preliminary results from this trial showedTable 1 – Patients and treatment regimens in randomize
Characteristics ECOG1496
MR* OBS MR
N 115 113 505
Age (y)
Median (range) 58 (30-84)§ 54 (30-84)§ 57 (26
Z60, n (%) 47 (41) 38 (34) 176 (3
Advanced stage (3/4), n (%) 73 (64)ǁ 72 (64)ǁ 459 (9
Sex: male, n (%) 59 (51) 62 (55) 270 (5
FLIPI score, n (%)
Low 23 (26) 24 (27) 106 (2
Intermediate 32 (36) 32 (36) 183 (3
High 33 (38) 33 (37) 215 (4
B symptoms, n (%) 22 (19) 34 (30) 160 (3
Induction therapy, % CVP CVP R-CHO
R-CVP
R-FCM
CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; comb,
sone; ECOG, Eastern Cooperative Oncology Group; FCM, ﬂudarabine with
FLIPI, the Follicular Lymphoma International Prognostic Index; FLU, ﬂ
Primary RItuximab and MAintenance; R, rituximab; RIT, radioimmunoth
* Rituximab 375 mg/m2 once a week for 4 wk every 6 mo for 2 y.
† Rituximab 375 mg/m2 every 8 wk for 2 y.
‡ Rituximab 250 mg/m2 on day 7 and day 0 followed on day 0 by 90Y-i
§ The range is for all FL patients in the trial.
ǁ Only stage 4 reported.similar partial response to the complete response conversion rate,
no signiﬁcant difference in OS, and a superior 3-year PFS for MR. As
indicated above, however, studies comparing frontline strategies in
FL may require more than a decade of follow-up to demonstrate
difference in OS. These data remain immature, and longer follow-
up is awaited for a more comprehensive comparison of survival
beneﬁts for the two approaches.
In clinical practice, MR is commonly used. An analysis based
on the largest prospective study of FL in the United States, the
National LymphoCare Study, showed that among 1186 patients
who received frontline rituximab-based induction therapy, 46%
received MR [19]. However, because a single dose of RIT consol-
idation may provide comparable efﬁcacy to MR for 2 years, RIT
could be preferred in some circumstances although it is much
less commonly used [20]. For MR and RIT consolidation, it is
unclear whether the additional costs are worth the beneﬁts when
compared with observation. In this study, we evaluated and
compared the economic impact of MR and RIT consolidation
versus observation, respectively, following the ﬁrst-line induction
therapy for patients with advanced-stage FL.Methods
General Approach
We developed three separate Markov models on the basis of three
phase 3 randomized clinical trials, respectively: one model compared
RIT with observation following the ﬁrst-line induction therapy based
on FIT [15,16], and two models compared 2-year MR with observation
based on the PRIMA trial [14] and the ECOG trial [13], respectively. We
refer to each model using the corresponding trial name throughout
the article. There existed differences in patient characteristics and
treatment regimens across the trials (Table 1). For example, thed trials.
PRIMA FIT
† OBS RIT‡ OBS
513 204 205
–79) 55 (22–84) 55 (29–78) 53 (27–74)
5) 180 (35) 58 (28) 48 (24)
1) 459 (89) 202 (99) 199 (97)
3) 263 (51) 97 (48) 103 (50)
1) 110 (21) 56 (37) 62 (43)
6) 187 (36) 58 (39) 54 (37)
3) 216 (42) 36 (24) 30 (21)
2) 156 (30) 46 (23) 42 (21)
P: 76 R-CHOP: 75 Chlorambucil: 10 Chlorambucil: 9
: 22 R-CVP: 22 CVP/COP: 26 CVP/COP: 26
: 3 R-FCM: 3 CHOP: 31 CHOP: 28
CHOP-like: 15 CHOP-like: 15
FLU-comb: 5 FLU-comb: 6
R-comb: 13 R-comb: 16
combination; CVP/COP, cyclophosphamide, vincristine, and predni-
mitoxantrone and cyclophosphamide; FIT, First-line Indolent Trial;
udarabine; MR, rituximab maintenance; OBS, observation; PRIMA,
erapy.
britumomab tiuxetan 14.8 MBq/kg; maximum of 1184 MBq.
Fig. 1 – Markov model. Description and data sources: a: PFS for each arm (i.e., MR/RIT/OBS), source: PRIMA/ECOG/FIT trial. b:
OS for each arm (i.e., MR/RIT/OBS), source: PRIMA/ECOG/FIT trial and the US life table. c: PFS after ﬁrst progression, source:
EROTC20981 trial (the second randomization, OBS arm without MR). d: OS after ﬁrst progression, source: EROTC20981 trial. e:
OS after second progression, source: Rummel et al. [25]. ECOG, Eastern Cooperative Oncology Group; EROTC, European
Organisation for Research and Treatment of Cancer; FIT, First-line Indolent Trial; MR, rituximab maintenance; OBS,
observation; PRIMA, Primary RItuximab and Maintenance; RIT, radioimmunotherapy.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 1 8 9 – 1 9 7 191induction therapy was chemotherapy in the ECOG trial and for most
patients in the FIT, but it was R-chemotherapy in the PRIMA trial. In
addition, the regimens of MR differed slightly between PRIMA and
ECOG trials. The differences in induction therapy affected patients’
outcomes. Therefore, it was not appropriate to perform an indirect
comparison between MR and RIT using the data from the trials with
different induction therapies. Instead, we built three separate models,
where each model inherited the speciﬁc clinical settings from the
corresponding clinical trial.
In each Markov model, we evaluated the lifetime cost and total
quality-adjusted life-years (QALYs) for MR, RIT, and observation
following ﬁrst-line induction therapy, respectively. Health states
deﬁned for the clinical course included 1) before ﬁrst progression, 2)
ﬁrst progression, 3) second progression, and 4) death (Fig. 1). The
structure for the models was determined on the basis of the typical
disease course of a patient with FL, in line with previously published
models for FL treatment [21,22]. The model simulated outcomes for
patients on the completion of ﬁrst-line induction therapy. During the
long disease course of FL, patients’ age also in part affects their
survival outcomes. Because FL is commonly diagnosed in patients
with a wide range of age, to better project the outcomes for the FL
population beyond the narrow age distribution of the clinical trial, we
sampled the initial age of each patient in the microsimulation from
the distribution of age at diagnosis of FL from the Surveillance,
Epidemiology, and End Results database between 1992 and 2009 [23].
The Markov model simulated transitions between health states
in each model cycle, which represented 1 month. We considered up
to three lines of treatment. Patients with relapsed FL were assumed
to receive R-CHOP/CHOP therapy without MR in the second-line
treatment [24] and bendamustine with rituximab (BR) in the third-
line treatment [25]. For ﬁrst- and second-line treatments, patients
could remain in the same health state, progress to the next line of
treatment, or die, with estimated probabilities based on clinical
data. Following the third-line treatment, only risks of death were
considered. We applied half-cycle corrections [26] for model param-
eters to address the possibility that state transitions could occur at
any time point within each cycle.
Costs were associated with each health state. We adopted the US
payer’s perspective, and therefore considered direct medical costs,
which captured the consumption of all resources directly attributable
to the treatment strategy. Direct nonmedical costs (e.g., transport
costs) and indirect costs (e.g., loss of productivity) were not consid-
ered in the model. All cost estimates were converted to 2013 US
dollars on the basis of the Consumer Price Index in the medical care
category [27]. We followed standard recommendations for conducting
health economic evaluation and discounted the clinical outcomes
and costs at the annual rate of 3% [28]. Each model was developed in
Treeage Pro 2011, and statistical analyses were performed in R.Progression Risk and Mortality
The probabilities of the ﬁrst progression in each model were
estimated on the basis of PFS curves in the published randomized
trials [13,14,16]. Risks of the second progression were estimated
on the basis of the PFS curve of the observation group in the
European Organisation for Research and Treatment of Cancer
phase III trial EORTC 20981 for patients with relapsed FL (i.e., R-
CHOP/CHOP therapy without MR) [22,24]. A further analysis based
on this trial has shown that the end points were not signiﬁcantly
different across different prior therapies, which enabled us to
safely assume that transition probabilities after the second-line
treatment were identical for each arm. To estimate the monthly
risk of progression, we used Engauge Digitizer to retrieve the data
points from each PFS curve plot, and ﬁtted parametric survival
models using these data points. We considered Weibull, log-
logistic, and Gompertz distributions for survival models. To
maintain consistency between the arms for comparisons, we
selected a common survival distribution that demonstrated good
ﬁt for all PFS and OS curves of treatment and observation arms in
each trial. In the ﬁnal analysis, we used log-logistic distributions
for ﬁrst- and second-line treatments and Gompertz distributions
for the third-line treatment. Other survival distributions were
tested in sensitivity analyses. We applied Bayes’ rule to derive the
monthly risk of progression, as a conditional probability of
progression in 1 month given that the patient has not progressed
yet. Risk estimates beyond the follow-up time of clinical trials
were extrapolated from the ﬁtted survival model. Because differ-
ences in survival outcomes continued to separate beyond the
median follow-up time, we assumed the duration of treatment
effect to be 6 years and risks of progression or death in MR and
RIT arms to be the same as those in observation arms after 6
years, which is in line with a previously published model of FL
treatment [22].
Mortality risk was deﬁned as the maximum of cause-speciﬁc
mortality and other-cause mortality at each cycle. The cause-
speciﬁc mortality before the ﬁrst progression was estimated on
the basis of OS curves for each arm in the PRIMA trial, the ECOG
trial, and FIT, and cause-speciﬁc mortalities of second and third-
line treatments were derived from the OS curves of CHOP/R-
CHOP treatment [24] and BR treatment [25] for relapsed FL,
respectively. Other-cause mortality for each age group was
estimated from the US life tables [29].
Utility and Cost Estimates
The HRQOL for MR and RIT consolidation has been assessed in
clinical studies separately. We used the health utility estimates
from the published literature. The utilities were estimated as 0.88
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and 0.84 for RIT and 0.83 for observation in the FIT model [17]
before the ﬁrst progression, 0.79 after the ﬁrst progression, 0.62
after the second progression, and 0 for the death state [22,30–32].
Only direct costs were considered in this study, including drug
costs, administration costs, monitoring costs, and adverse event
costs. The drug costs for MR and RIT consolidation were calcu-
lated on the basis of dosing for the regimens in each trial, while
no drug costs were incurred in the observational arm. The
infusion dosages for FL treatments were computed on the basis
of a body surface area with a mean value of 1.835 m2 [22]. The
wholesale acquisition cost [33] was used for the unit cost of each
drug. The cost estimate for the second-line treatment was based
on an established practice pattern for relapsed FL previously
described in a published FL modeling study [22], and the cost of
third-line treatment was based on the bendamustine and ritux-
imab regimen [25].
Unlike RIT, which has only one-time drug infusion, MR and
second- or third-line treatment extend for more than one model
cycle and require multiple drug administrations (e.g., 2 years for
MR, 18 weeks for R-CHOP/CHOP, and 16 weeks for BR). We divided
the total costs of drugs and administration by the complete
treatment duration, and allocated the same amount in each
month over the treatment periods. This way, only the resources
used and the corresponding costs occurred to that point were
attributed to individual patients in the models because patients
in the model could die or progress to the next line of treatment
during any model cycle as in clinical practice.
We estimated the cost of grade 3/4 adverse events on the basis
of our clinical coauthors’ expert opinion in the management
strategies for each adverse event. We assumed that patients with
grade 3/4 infection/febrile neutropenia were hospitalized and
others were managed as outpatients. The cost of hospitalization
included inpatient physician service fees and hospital reimburse-
ment based on the length of stay diagnosis-related group (DRG)
code corresponding to the adverse event [34]. For other hemato-
logical adverse events, the cost included outpatient visit cost and
the cost of the materials for the adverse event management (see
Appendix 1 for details in Supplemental Materials found at http://
dx.doi.org/10.1016/j.jval.2014.12.017). For each treatment strategy,
the cost of each adverse event was obtained by multiplying the
incidence and the unit cost for each type of adverse event.
Drug administration and adverse event costs were calculated
using the Medicare physician fee schedule for 2013 [35]. Each
medical service performed by a physician is associated with a
speciﬁc Health Care Procedure Coding System code and/or the
Current Procedure Terminology code. For each procedure, we
determined its relative value units on the basis of the Health Care
Procedure Coding System/Current Procedure Terminology code
from the Centers of Medicare & Medicaid Services database [35],
and then computed the outpatient physician service cost on the
basis of relative value units [34]. Monitoring costs included the
costs of blood tests and physician visits every 3 months, and
costs of computed tomography scans every 6 months, which
were independent of the treatment arm and the current line of
treatment (Table 2).
Sensitivity Analysis
We conducted sensitivity analyses to evaluate the robustness of
the model and to address the uncertainty in parameter estima-
tion. Ranges and distributions of the parameters used in sensi-
tivity analysis are summarized in Table 2. Utilities were varied
over their 95% conﬁdence intervals. For each procedure, physi-
cian fees were adjusted by different geographic pricing cost index
adjustment factors, and the ranges of physician fees were
determined by the lowest and highest costs in the Centers ofMedicare & Medicaid Services fee schedule. Similarly, to deﬁne
the ranges for DRG-based hospital reimbursement, we computed
the DRG rate for each of 3500 providers in the United States [34]
and found the lowest and the highest DRG rates. Drug costs were
varied within 10% of their baseline values. We acknowledge
that the treatment duration effect may be conservative for ECOG
and FIT models because these trials have a longer follow-up time.
Therefore, we varied the duration from the minimum follow-up
time of 3 years to lifetime in the sensitivity analysis.
In univariate sensitivity analysis, we examined the effect of
each parameter on incremental cost-effectiveness ratios (ICERs)
separately. In probabilistic sensitivity analysis (PSA), parameters
were sampled simultaneously according to their sampling dis-
tributions. We followed recommended distributions based on
parameter types, and assumed lognormal distribution for cost
and beta distribution for utility and incidence of adverse events
(Table 2) [36]. We ran 10,000 replications for the PSA.
In secondary sensitivity analyses examining the robustness of
the model structure, the models were evaluated on the basis of
different ﬁtted survival distributions. In addition, we compared
MR and observation in a combined model, in which we aggre-
gated the ﬁtted PFS and OS curves of each arm using the
weighted log-relative-risk method [37], and estimated risks on
the basis of aggregated survival curves. Other model parameters
were combined by taking the average of the estimates from
multiple studies weighted by the sample size of each study.Results
In primary analyses, effectiveness and costs were compared
within each clinical trial. Based on the PRIMA study, MR therapy
provided 7.64 QALYs at a cost of $112,780 compared with 6.55
QALYs at a cost of $68,855 for the observation arm. Based on the
ECOG study, MR therapy provided 6.51 QALYs at a cost of $124,405
compared with 5.11 QALYs at a cost of $72,066 for the observation
arm. Based on FIT, RIT therapy provided 6.60 QALYs at a cost of
$115,011 compared with 5.57 QALYs at a cost of $73,098 for the
observation arm. The ICERs for MR were $40,335 and $37,412/
QALY gained in the PRIMA study and the ECOG study, respec-
tively, and the ICER for RIT was $40,851/QALY gained based on
FIT. Our model also estimated total projected life-years (LYs)
without quality adjustment and provided the effectiveness and
cost estimates by treatment period as summarized in Table 3.
Results of univariate sensitivity analyses are presented in the
tornado diagrams (Fig. 2). The most inﬂuential common factors
for all three models included utility before ﬁrst progression in the
maintenance/consolidation arm or the observation arm in each
trial, drug cost for MR and RIT, duration of treatment effect, and
discount factor. In the PSA, the incremental cost and effective-
ness from 10,000 samples are shown in the scatterplots for each
trial (see Appendix 2 in Supplemental Materials found at http://
dx.doi.org/10.1016/j.jval.2014.12.017). The results of the PSA are
also presented in the cost-effectiveness acceptability curve
(Fig. 3). The cost-effectiveness acceptability curves showed that
MR and RIT consolidation is cost-effective compared with obser-
vation at $50,000/QALY willingness-to-pay threshold, with prob-
ability 58%, 74%, and 62% in the PRIMA, ECOG, and FIT model,
respectively. At a willingness-to-pay threshold of $100,000/QALY,
the probabilities become 79%, 92%, and 84%, respectively. The
models were also shown to be robust to the input risk estimates.
The results produced similar ICER estimates when different ﬁtted
survival models were used (see Appendix 3 in Supplemental
Materials found at http://dx.doi.org/10.1016/j.jval.2014.12.017). In
the combined model, MR provided an additional 1.13 QALYs (1.15
LYs) at the incremental cost of $46,234 compared with observa-
tion and the ICER was $40,956 per QALY gained.
Table 2 – Estimates, ranges, and distributions of model parameters.
Model input Value Minimum Maximum Distribution for PSA
BSA 1.835 m2
Cost of rituximab maintenance ($)*
PRIMA regimen (12 doses) 54,588
PRIMA regimen: monthly cost 2,275 2,047 2,502 Lognormal (μ ¼ 7.73, σ ¼ 0.10)†
ECOG regimen (16 doses) 72,784
ECOG regimen: monthly cost 3,033 2,729 3,336 Lognormal (μ ¼ 8.01, σ ¼ 0.10)
Cost of radioimmunotherapy consolidation ($) 46,566 41,910 51,223 Lognormal (μ ¼ 10.74, σ ¼ 0.10)
Cost of second-line treatment ($) [22]
Average cost of second-line therapies 46,504 41,854 51,155 Lognormal (μ ¼ 10.74, σ ¼ 0.10)
Cost of third-line treatment ($)
Bendamustine þ rituximab (four courses) 45,433 40,891 49,977 Lognormal (μ ¼ 10.72, σ ¼ 0.10)
Administration cost ($)‡
Monthly administration cost of chemotherapy§
PRIMA regimen 88 62 117 Lognormal (μ ¼ 4.43, σ ¼ 0.30)
ECOG regimen 117 82 155 Lognormal (μ ¼ 4.72, σ ¼ 0.30)
Radioimmunotherapy administration cost
Radiopharmaceutical therapy, radiolabeled-
monoclonal antibody, IV (CPT: 79403)
190 151 234 Lognormal (μ ¼ 5.22, σ ¼ 0.22)
Monitoring cost ($)
CT scans: chest/abdomen/pelvis (CPT: 72129, 74160,
72193)
828 598 1,083 Lognormal (μ ¼ 6.68, σ ¼ 0.29)
Laboratory tests [50] 76 68 84 Lognormal (μ ¼ 4.33, σ ¼ 0.10)
Other procedures cost ($)
Outpatient physician visits (CPT: 99213) 50 43 66 Lognormal (μ ¼ 3.88, σ ¼ 0.23)
Inpatient physician visits
First visit (CPT: 99222) 135 117 179
Subsequent visits (CPT: 99232) 70 62 94
Discharge visit (CPT: 99238) 71 61 93
Blood transfusion (CPT: 36430) 35 23 47
Adverse event cost ($)||
Anemia 1,881 1,826 1,910 Lognormal (μ ¼ 7.54, σ ¼ 0.02)
Neutropenia 3,066 2,758 3,384 Lognormal (μ ¼ 8.02, σ ¼ 0.10)
Febrile neutropenia/infection 11,566 7,092 27,656 Lognormal (μ ¼ 9.07, σ ¼ 0.76)
Thrombocytopenia 1,086 593 1,139 Lognormal (μ ¼ 6.96, σ ¼ 0.23)
Incidence of adverse events
PRIMA study
MR arm, neutropenia 0.040 0.020 0.060 Beta (a ¼ 3.84, b ¼ 92.16)¶
MR arm, febrile neutropenia/infection 0.040 0.020 0.060 Beta (a ¼ 3.84, b ¼ 92.16)
OBS arm, neutropenia 0.010 0 0.040 Beta (a ¼ 0.99, b ¼ 98.01)
OBS arm, febrile neutropenia/infection 0.010 0 0.040 Beta (a ¼ 0.99, b ¼ 98.01)
MR and OBS arm, anemia, thrombocytopenia 0.005 0 0.040 Beta (a ¼ 0.03, b ¼ 5.50)
ECOG study
MR arm, neutropenia 0.030 0.020 0.050 Beta (a ¼ 3.88, b ¼ 125.45)
MR arm, febrile neutropenia/infection 0.010 0 0.020 Beta (a ¼ 3.96, b ¼ 392.04)
OBS arm, neutropenia 0.010 0 0.040 Beta (a ¼ 0.99, b ¼ 98.01)
OBS arm, febrile neutropenia/infection 0.010 0 0.040 Beta (a ¼ 0.99, b ¼ 98.01)
MR and OBS arm, anemia, thrombocytopenia 0.005 0 0.040 Beta (a ¼ 0.03, b ¼ 5.50)
FIT
RIT arm, neutropenia 0.667 0.400 0.700 Beta (a ¼ 136.04, b ¼ 67.92)
RIT arm, febrile neutropenia/infection 0.079 0.040 0.120 Beta (a ¼ 3.68, b ¼ 42.95)
RIT arm, anemia 0.034 0.018 0.228 Beta (a ¼ 4.36, b ¼ 123.93)
RIT arm, thrombocytopenia 0.608 0.400 0.650 Beta (a ¼ 82.15, b ¼ 52.96)
OBS arm, neutropenia 0.025 0 0.040 Beta (a ¼ 2.71, b ¼ 105.63)
OBS arm, febrile neutropenia/infection 0.024 0 0.040 Beta (a ¼ 2.20, b ¼ 89.30)
OBS arm, anemia 0 0 0.040 Beta (a ¼ 0.03, b ¼ 5.50)
OBS arm, thrombocytopenia 0 0 0.040 Beta (a ¼ 0.03, b ¼ 5.50)
Utility
No progression, MR 0.88 0.81 0.95 Beta (a ¼ 18.96, b ¼ 2.59)
No progression, RIT 0.84 0.77 0.91 Beta (a ¼ 23.04, b ¼ 4.39)
No progression, OBS
PRIMA study 0.88 0.81 0.95 Beta (a ¼ 18.96, b ¼ 2.59)
FIT study 0.83 0.76 0.90 Beta (a ¼ 23.90, b ¼ 4.90)
Combined 0.87 0.79 0.94 Beta (a ¼ 18.55, b ¼ 2.86)
continued on next page
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Table 2 – Continued
Model input Value Minimum Maximum Distribution for PSA
After the ﬁrst progression 0.79 0.72 0.86 Beta (a ¼ 26.75, b ¼ 7.11)
After the second progression 0.62 0.48 0.76 Beta (a ¼ 7.45, b ¼ 4.57)
Discount factor 0.03 0 0.05 -
Effective horizon (mo) 72 36 Until
progression
-
BSA, body surface area; CPT, Current Procedure Terminology; CT, computed tomography; ECOG, Eastern Cooperative Oncology Group; FIT,
First-line Indolent Trial; MR, rituximab maintenance; OBS, observation; PRIMA, Primary RItuximab and MAintenance; PSA, probabilistic
sensitivity analysis; RIT, radioimmunotherapy; WAC, wholesale acquisition cost.
* WAC for the unit cost of the drug [33], values of drug costs varied by 10% in one-way sensitivity analysis, and lognormal distributions were
used in the PSA.
† Parameters of lognormal distribution are determined on the basis of mean and standard deviation (SD) of the variable (SD is estimated on the
basis of half of the range of parameter value).
‡ For the cost estimates of procedures, we used the national payment amount (i.e., geographic pricing cost index ¼ 1), conversion factor for
2013 was $34.02, and all the cost estimates were based on the CY 2013 PFS ﬁnal rule [35].
§ Chemotherapy administration takes 3 h for the ﬁrst course and 2 h for subsequent courses.
|| See Appendix 1 for details.
¶ Parameters of Beta distribution are determined on the basis of the point estimate and the sample size in the original study.
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MR and RIT consolidation are two commonly considered strat-
egies following the ﬁrst-line induction therapy for patients with
FL to improve patients’ response and survival without disease
progression. In this study, we evaluated the long-term beneﬁts
and costs of these two treatments, MR and RIT, compared with
observation. In our model, both MR and RIT showed that patients’
total QALYs were improved at reasonable costs, with the esti-
mated ICERs below the threshold of $50,000 per additional QALY.
We assessed the uncertainty in the model results and demon-
strated moderate conﬁdence of cost-effectiveness for MR and RIT,
with about 60% likelihood of an ICER of $50,000/QALY or less and
80% of an ICER of $100,000/QALY or less.Table 3 – Base-case result.
Model output PRIMA model
MR OB
LYs
Before ﬁrst progression 6.239 4.5
Total LYs 9.376 8.2
QALYs
Before ﬁrst progression 5.491 3.9
Total QALYs 7.643 6.5
Costs ($)
Adverse event 600 1
Before ﬁrst progression 63,015 9,6
First progression to second progression 26,612 31,4
After second progression 23,154 27,7
Total 112,781 68,8
Incremental values
LYs 1.0
QALYs 1.0
Costs ($) 43,9
Incremental cost-effectiveness ratios
Incremental cost per LY gained 39,9
Incremental cost per QALY gained 40,3
ECOG, Eastern Cooperative Oncology Group; FIT, First-line Indolent Trial
Primary RItuximab and MAintenance; PSA, probabilistic sensitivity analyDifferent induction therapies may affect the projected effec-
tiveness of MR, RIT, and observation. Given that most of the
patients in FIT received frontline chemotherapy without ritux-
imab whereas all patients in the PRIMA trial received R-
chemotherapy (Table 1), the two studies did not have similar
PFS and OS in their observation arm. We observed that survival
curves for the RIT arm of the FIT model were comparable with
those for the observation arm of the PRIMA model, which led to
similar model outputs: 6.60 QALYs (8.48 LYs) and 6.55 QALYs (8.28
LYs) for each arm, respectively. This was validated externally by a
recent comparison between R-CHOP followed by observation and
CHOP followed by RIT (I131 tositumumab) in a phase 3 random-
ized clinical trial (S0016) [38]. This study showed that both
strategies had outstanding PFS and OS but there was noECOG model FIT model
S MR OBS RIT OBS
20 4.751 2.451 5.042 3.204
77 8.136 6.744 8.481 7.447
77 4.181 2.157 4.235 2.659
53 6.505 5.107 6.597 5.572
61 222 161 3,683 354
20 71,515 5,160 61,028 6,979
63 28,216 35,630 28,913 35,184
72 24,675 31,276 25,071 30,937
56 124,406 72,066 115,012 73,099
99 1.391 1.034
89 1.399 1.026
25 52,339 41,913
68 37,627 40,535
35 37,412 40,851
; LY, life-year; MR, rituximab maintenance; OBS, observation; PRIMA,
sis; QALY, quality-adjusted life-year; RIT, radioimmunotherapy.
Fig. 2 – Tornado diagrams of most inﬂuential variables to ICERs. CT, computed tomography; ECOG, Eastern Cooperative
Oncology Group; FIT, First-line Indolent Trial; ICER, incremental cost-effectiveness ratio; MR, rituximab maintenance; OBS,
observation; PRIMA, Primary RItuximab and Maintenance; RIT, radioimmunotherapy.
Fig. 3 – Cost-effectiveness acceptability curves. ECOG, Eastern Cooperative Oncology Group; FIT, First-line Indolent Trial;
PRIMA, Primary RItuximab and Maintenance; QALY, quality-adjusted life-year.
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ing 2-year PFS).
The cost before ﬁrst progression wasmainly driven by drug cost
in each trial. According to the wholesale acquisition cost, RIT costs
approximately $46,000, and a full course of MR costs approximately
$54,000 (12 courses) in the PRIMA trial and $72,000 (16 courses) in
the ECOG trial. Adverse event costs were more signiﬁcant for RIT
than for MR and observation, due to the high incidences of anemia
and thrombocytopenia following RIT consolidation. This ﬁnding is
in line with the high incidence of adverse events reported in a
series of phase 2 studies [39–44]. However, patients in the obser-
vation arms progressed earlier, leading to higher costs after ﬁrst
progression. These models help to describe and quantify to what
extent the additional costs of treatment and adverse events
following frontline therapy for FL are counterbalanced by the
beneﬁt of maintaining more prolonged remissions.
Sensitivity analyses showed that the utility before ﬁrst pro-
gression following MR or RIT was the most important factor in all
three models, which suggests that improving patients’ HRQOL
following MR or RIT consolidation could make these approaches
more cost-effective. Limited data, however, exist on the HRQOL
associated with MR or RIT based on small cohorts in trials: a UK
study [31] and the FIT study. Additional assessments of the
HRQOL for patients with FL in the ﬁrst remission would be
warranted to better understand the robustness of these ﬁndings.
Moreover, the duration of treatment beneﬁt also played an
important role in the cost-effectiveness of MR and RIT. The
models also showed that treatment can become more cost-
effective if the treatment can prolong the duration of remission
and reduce the risk of disease-related mortality. The cost-
effectiveness of MR in the PRIMA model in this study was in line
with a published cost-effectiveness analysis [22]. The estimates
of total QALYs for both arms were slightly lower in our model,
which could be attributed to differences in the initial age
distribution and the ﬁtted distribution of survival curves.
Our study has limitations. First, there are differences in
induction therapies and patient characteristics across trials,
which may inﬂuence the model parameters, such as risk and
utility estimates. This also limited our ability to combine study
results and to directly compare the ICERs of MR and RIT. Second,
the utilities for patients in MR and observation in PRIMA and
ECOG models were estimated from a separate UK study [31]
because health utility estimates are not available from the
original trials. More comprehensive estimates of utilities for the
general population would further improve the accuracy and
robustness of the model. Third, we did not differentiate the
health states on the basis of response to the treatment owing
to lack of data concerning response-speciﬁc utility and survival
estimates. In addition, in clinical practice, disease progression
does not necessarily indicate an immediate treatment for
patients with FL. Therefore, time-to-next-treatment is preferable
to PFS in representing the transition to the next line of treatment.
Time-to-next-treatment data were not available, however, for the
ECOG trial or relapsed FL studies.
Our analyses showed that the cost-effectiveness of MR and
RIT was comparable to that of other treatments for advanced-
stage FL, which replaced an older standard of care. For example,
the ICERs were $20,000 to 30,000 per QALY gained for ﬁrst-line R-
chemotherapy regimens compared with chemotherapy alone
[30,45,46], for ﬁrst-line BR compared with R-chemotherapy [47],
and for MR compared with observation for relapsed FL [32,48].
Despite differences in model settings, costs, and health systems
between countries, these studies revealed a similar magnitude of
ICERs of these treatment strategies for indolent lymphoma. Based
on our model results, MR and RIT consolidation following ﬁrst-
line induction therapy for patients with advanced-stage FL also
appeared to be reasonably cost-effective approaches.However, the favorable cost-effectiveness proﬁle of MR and
RIT does not imply a uniform approach of selecting treatments in
the general population. For an individual patient, selection of
either approach or observation should depend on individual
patient characteristics, such as performance status. The risks of
severe adverse events induced by RIT (such as cytopenias) should
also be considered, although these have a limited effect on the
cost-effectiveness of RIT. Moreover, the length of treatment may
also affect the decision. MR requires repeated treatment over 2
years, whereas RIT requires only one drug infusion, which may
be more accessible to patients in certain circumstances [49].
In summary, we used the same modeling framework and
consistent parameter estimates to evaluate the cost-effectiveness
of MR and RIT compared with observation following frontline
treatment for patients with FL. Both strategies showed favorable
cost-effectiveness proﬁle for these approaches to prevent FL
disease progression when compared with observation following
frontline therapy. Although differences in induction therapies in
these three trials should be noted when the ICERs of mainte-
nance/consolidation therapies are compared, this work provides
the most comprehensive assessment to date comparing the cost-
effectiveness of these strategies. Future analyses comparing
these approaches would beneﬁt from more direct assessment of
the HRQOL during the period of MR or observation following
frontline therapy and long-term follow-up data from randomized
trials directly comparing MR and RIT consolidation.
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